Lord Abbett Health Care F holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Lord Abbett Health Care Fund Class F LHCFX
- NAV / 1-Day Return 24.06 / −2.20 %
- Total Assets 8.7M
-
Adj. Expense Ratio
0.780%
- Expense Ratio 0.780%
- Distribution Fee Level Below Average
- Share Class Type No Load
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.24%
- Turnover 91%
USD | NAV as of Jul 11, 2026 | 1-Day Return as of Jul 11, 2026, 12:41 AM GMT+0
Morningstar’s Analysis LHCFX
Will LHCFX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 43.0
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 10.78 | 856,375 | Healthcare |
AstraZeneca PLC | 4.75 | 377,133 | Healthcare |
Gilead Sciences Inc | 4.48 | 355,836 | Healthcare |
Guardant Health Inc | 4.01 | 318,908 | Healthcare |
UnitedHealth Group Inc | 3.91 | 310,713 | Healthcare |
Natera Inc | 3.24 | 257,099 | Healthcare |
Johnson & Johnson | 3.20 | 254,398 | Healthcare |
CVS Health Corp | 3.13 | 248,739 | Healthcare |
argenx SE | 2.79 | 222,024 | Healthcare |
Galderma Group AG Registered Shares | 2.75 | 218,283 | Healthcare |